News

MentalHealth.com Acquires Online Mental Health Platform and Community

SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2024 / Leading patient-first health technology company MentalHealth.com is pleased to announce…

2 years ago

Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)

KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage…

2 years ago

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference

Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to…

2 years ago

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in…

2 years ago

GeneDx Announces Preliminary 2023 Financial Results

Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with…

2 years ago

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s…

2 years ago

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular…

2 years ago

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Advanced technology enables the land-based production of omega-3 (EPA+DHA) in Camelina potentially representing a novel solution to the market need…

2 years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Achieving scale with pro forma full year 2023 revenue of approximately $192 millionSOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE…

2 years ago

Evaxion Announces Plan to Implement ADS Ratio Change

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

2 years ago